600422 KPC Pharmaceuticals, Inc.
- 22.72
- -0.15-0.66%
KPC Pharmaceuticals, Inc. News
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
Huayuan Securities released a research report on April 25 stating that it gave Kunming Pharmaceutical Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) deepening the 37 industrial chain and strategically positioning the Yinf
Huayuan Securities released a research report on April 25 stating that it gave Kunming Pharmaceutical Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) deepening the 37 industrial chain and strategically positioning the Yinfa economy; 2) Kunming traditional Chinese medicine for more than 600 years to create a leader in fine Chinese medicine. (Mainichi Keizai Shimbun)
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has
Wanlian Securities released a research report on April 24 stating that it gave China Resources 39 (000999.SZ) a purchase rating. The main reasons for the rating include: 1) the CHC business has achieved rapid growth, and the prescription drug business has maintained a positive development trend; 2) the integration work of the Kunyao Group is progressing steadily; 3) Continued development or introduction of innovative drugs, improved innovative drugs, generic drugs, classic famous recipes, etc. (Mainichi Keizai Shimbun)
Earnings Tell The Story For KPC Pharmaceuticals,Inc (SHSE:600422)
KPC Pharmaceuticals,Inc's (SHSE:600422) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a sell right now compared to the market in China, where around half of the companies have P
China Resources Pharmaceutical (03320.HK): KPC achieved total revenue of 1,853 billion yuan in the first quarter
Gelonghui, April 22 | China Resources Pharmaceutical (03320.HK) announced that in the first quarter of 2024, KPC achieved total operating revenue of 1,853 billion yuan, a decrease of 3% year on year; net profit of 121 million yuan, a decrease of 10% year on year.
Kunming Pharmaceutical Group (600422): Steady improvement in business quality, non-growth in line with expectations
Core view In 2024, the company achieved operating income, net profit attributable to mother, and net profit after deduction of 1,853 million yuan, 119 million yuan, and 113 million yuan respectively, with year-on-year increases of -3.01% and -9.41 million yuan, respectively.
Kunming Pharmaceutical Group (600422): Local fine-tuning is expected to be lower and higher throughout the year
1Q24 deducted non-profit increased 9%. The company announced 1Q24 revenue of 1.85 billion yuan, net profit to mother of 120 million yuan, and deducted non-net profit of 110 million yuan, with year-on-year changes of -3%, -9%, and 9%. The decline in revenue was mainly due to foreign aid
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the thre
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the three major gold products have performed brilliantly; 2) the “777” brand was officially launched, and the high-quality development of the entire 37 industry chain continues to advance. (Mainichi Keizai Shimbun)
Kunming Pharmaceutical Group (600422): The “Kunming Traditional Chinese Medicine 1381” brand achieved initial results, and the three major gold products performed brilliantly
Key investment events: The 24Q1 company achieved operating income of 1,853 billion yuan (-3.01%, same ratio, same below), realized net profit to mother 119 million yuan (-9.41%), and achieved net profit of 1.13 billion yuan after deduction of non-return to mother
Kunming Pharmaceutical Group (600422) Company Review Report: Short-term pressure on Q1 performance, Kunming Traditional Chinese Medicine accelerates growth
Incident: The company released its 2024 quarterly report, 2024Q1. The company achieved operating income of 1,853 billion yuan, a year-on-year decrease of 3.01%; net profit to mother was 119 million yuan, a year-on-year decrease of 9.41%; net profit not attributable to mother was deducted
Kunming Pharmaceutical Group (600422.SH) reported first-quarter results, net profit of 119 million yuan, a year-on-year decrease of 9.41%
Kunming Pharmaceutical Group (600422.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Kunming Pharmaceutical Group (600422): Yinfa Health Industry Leader Sets Sail Again in Strategic Reshaping
Equity innovation is moving towards a new journey, and the business structure is being reshaped and optimized. The predecessor of KPC, “Kunming Pharmaceutical Factory”, was established in 1951. The company went through overall restructuring in 1995 and successfully listed in 2000. After years of development, the company was formed
Kunyao Group Receives Clinical Trial Approval for FMF Drug
China's National Medical Products Administration has approved Kunyao Group's (SHA:600422) plan to carry out a clinical trial of its drug against familial Mediterranean fever of FMF, according to a Wed
Kunming Pharmaceutical Group (600422.SH): “KPC-149 Oral Solution” approved to carry out related clinical trials
Kunming Pharmaceutical Group (600422.SH) announced that the company recently received KPC- issued by the State Drug Administration...
Express News | Kunming Pharmaceutical Group: Obtaining the KPC-149 Oral Solution Drug Clinical Trial Approval Notice
Express News | China Resources 39: The company is expected to achieve double-digit revenue growth in 2024
KPC PharmaceuticalsInc's (SHSE:600422) Shareholders May Want To Dig Deeper Than Statutory Profit
Following the solid earnings report from KPC Pharmaceuticals,Inc (SHSE:600422), the market responded by bidding up the stock price. However, we think that shareholders should be cautious as we found
Kunming Pharmaceutical Group (600422): Doubling the industrial revenue target by the end of 2028 lays the foundation for medium- to long-term high growth
Matters: The company announced its 2023 annual report, achieving revenue of 7.703 billion yuan (-6.99%), net profit of 445 million yuan (+16.05%), and net profit of 335 million yuan after deducting non-return to mother (+33.45%)
KPC Pharmaceuticals,Inc's (SHSE:600422) Market Cap Surged CN¥560m Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Key Insights KPC PharmaceuticalsInc's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is held by
Kunming Pharmaceutical Group (600422): Smooth integration strategy clearly released five-year plan to guide growth
In 2023, the company achieved revenue of 7.703 billion yuan (-6.99% YoY), net profit attributable to mother of 445 million yuan (YoY +16.05%), net profit not attributable to mother of 335 million yuan (YoY +33.45%)
Analysis
Price Target
No Data
